ASCO Poster

A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.Klazien Matter-Walstra, Matthias Schwenkglenks, Peter Brauchli, Dirk Klingbiel, Konstantin J. Dedes;J Clin Oncol 34, 2016 (suppl; abstr 567)